US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Xtrackers Nifty 500 India ETF

22.58

+0.11570.52%

Post-market: 22.580.00000.00%16:10 EDT

Volume:1K

Turnover:24.04K

Market Cap:4.52M

PE:- -

High:22.58

Open:22.51

Low:22.51

Close:22.47

52wk High:27.40

52wk Low:20.52

Shares:200.00K

Float Shares:200.00K

Volume Ratio:2.13

T/O Rate:0.53%

Dividend:0.08

Dividend Rate:0.35%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial

Ab&B Bio-Tech Wins Dual China-U.S. IND Nod for First mRNA Mpox Vaccine

AB&B BIO-TECH-B's mRNA Monkeypox Vaccine Candidate Receives IND Approval from China's CDE

ASCLETIS-B Receives FDA Clearance for Phase I Study of Its Monthly Subcutaneous GLP-1R/GIPR Dual Agonist Peptide ASC35 in Obesity

INNOGEN-B Shares Surge Over 17% Following NMPA Approval for Adolescent Weight Loss Trial of Esupaglutide α

India Ratings Affirms IND AA/Stable for JSW Energy Barmer Loans

Press Release: SL Science Holding Limited Reports Full Year 2025 Financial Results

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Starbucks Intensifies Focus on India with Ambitious Store Expansion Plan

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

Calidi receives pre-IND regulatory feedback from FDA for CLD-401

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

XBiotech to enroll patients in vilamakitug trial following FDA review

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

HBM Holdings (SEHK:2142) Stock Valuation After New IND Milestone For Cancer Antibody HBM7004

Simply Wall St.

Shanghai Bao Pharma Wins U.S. FDA IND Clearance for First Subcutaneous Ceftriaxone Candidate

HBM Wins China IND Nod for Bispecific Cancer Antibody HBM7004

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/IND/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":22.5807,"timestamp":1789156800000,"preClose":22.465,"halted":0,"volume":1065,"hourTrading":{"tag":"盘后","latestPrice":22.5807,"preClose":22.5807,"latestTime":"16:10 EDT","volume":61,"amount":1373.96278,"timestamp":1789157404632,"change":0,"changeRate":0,"amplitude":0.002688},"delay":0,"changeRate":0.005150233696861801,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"Post-Mkt","change":0.1157,"latestTime":"09-11 18:35:16 EDT","open":22.51,"high":22.5807,"low":22.51,"amount":24036,"amplitude":0.003147,"askPrice":33.78,"askSize":200,"bidPrice":22.23,"bidSize":22,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789171200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":22.465,"sharesOutstanding":200001,"nav":22.614,"aum":4522844.8,"dividendRate":0.003481,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":22.5807,"preClose":22.5807,"latestTime":"16:10 EDT","volume":61,"amount":1373.96278,"timestamp":1789157404632,"change":0,"changeRate":0,"amplitude":0.002688},"volumeRatio":2.134269},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.134269,"shares":200001,"dividePrice":0.0786,"high":22.5807,"amplitude":0.003147,"preClose":22.465,"low":22.51,"week52Low":20.515,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":22.5807,"committee":-0.801802,"eps":0,"divideRate":0.003481,"volume":1065,"delay":0,"ttmEps":0,"open":22.51,"prevYearClose":24.78,"prevWeekClose":23.125,"prevMonthClose":23.145,"prevQuarterClose":22.88,"fiveDayClose":23.195,"twentyDayClose":23.2218,"sixtyDayClose":22.81},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[{"date":"2026-06-18","symbol":"IND","amount":0.07775,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-18","defaultRemindTime":1781789400000,"name":"Xtrackers Nifty 500 India ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-18","currency":"USD","dateTimestamp":1781755200000,"payDate":"2026-06-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-18","recordDate":"2026-06-18","paymentDate":"2026-06-26","value":0.07775,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645383673","title":"Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645383673","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645383673?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:17","pubTimestamp":1782217020,"startTime":"0","endTime":"0","summary":"Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June  23, 2026  (GLOBE NEWSWIRE) --  Silo Pharma (Nasdaq: SILO) (“S","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/23/3315946/0/en/Silo-Pharma-Reports-Positive-Stability-Data-for-SPC-15-PTSD-Treatment-Advancing-Program-Toward-First-in-Human-Clinical-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443895.HKD","LU1363072403.SGD","IE00BFXG1179.USD","BK4006","BK4135","IE00BKVL7J92.USD","LU2746668461.USD","CNS","LU0149725797.USD","LU0267386448.USD","LU0971096721.USD","LU2237443382.USD","LU2237443622.USD","LU2237443465.HKD","IE00BHPRN162.USD","LU0882574139.USD","SPC","LU2237443978.SGD","LU0170899867.USD","IE00B1BXHZ80.USD","IE00BZ1G4Q59.USD","LU2237443549.SGD","LU2746668974.SGD","IND","CMC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645838226","title":"Ab&B Bio-Tech Wins Dual China-U.S. IND Nod for First mRNA Mpox Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2645838226","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645838226?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:00","pubTimestamp":1782212450,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech CO., LTD. JS Class H ( ($HK:2627) ) has issued an announcement. Ab&B Bio-Tech CO., LTD. JS, a China-based vaccine developer, has secu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abb-bio-tech-wins-dual-china-u-s-ind-nod-for-first-mrna-mpox-vaccine?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abb-bio-tech-wins-dual-china-u-s-ind-nod-for-first-mrna-mpox-vaccine?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121897103","title":"AB&B BIO-TECH-B's mRNA Monkeypox Vaccine Candidate Receives IND Approval from China's CDE","url":"https://stock-news.laohu8.com/highlight/detail?id=1121897103","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121897103?lang=en_us&edition=fundamental","pubTime":"2026-06-23 18:12","pubTimestamp":1782209561,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (ASX: 02627) has announced that, following the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), the Center for Drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627","159646","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157125267","title":"ASCLETIS-B Receives FDA Clearance for Phase I Study of Its Monthly Subcutaneous GLP-1R/GIPR Dual Agonist Peptide ASC35 in Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=1157125267","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157125267?lang=en_us&edition=fundamental","pubTime":"2026-06-23 18:10","pubTimestamp":1782209421,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) has announced the receipt of an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the Phase I clinical study of its drug candidate,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4585","BK4144","BK1515","IND","BK4588","GIPR","BK1191","LABU","GLP","BK1574","BK4590","BK4160","01477","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123803607","title":"INNOGEN-B Shares Surge Over 17% Following NMPA Approval for Adolescent Weight Loss Trial of Esupaglutide α","url":"https://stock-news.laohu8.com/highlight/detail?id=1123803607","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123803607?lang=en_us&edition=fundamental","pubTime":"2026-06-23 09:58","pubTimestamp":1782179905,"startTime":"0","endTime":"0","summary":"Shares of INNOGEN-B (02591) are currently trading sharply higher, with gains exceeding 17%. At the time of writing, the stock is up 14.03% to HK$8.94, with a trading turnover of HK$45.71 million.The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4588","VXUS","IND","BK4585","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644050436","title":"India Ratings Affirms IND AA/Stable for JSW Energy Barmer Loans","url":"https://stock-news.laohu8.com/highlight/detail?id=2644050436","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644050436?lang=en_us&edition=fundamental","pubTime":"2026-06-19 23:47","pubTimestamp":1781884031,"startTime":"0","endTime":"0","summary":"An update from JSW Energy Limited ( ($IN:JSWENERGY) ) is now available. India Ratings and Research has affirmed an “IND AA/Stable” credit rating fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/india-ratings-affirms-ind-aa-stable-for-jsw-energy-barmer-loans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/india-ratings-affirms-ind-aa-stable-for-jsw-energy-barmer-loans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNDmain","AA","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644390000","title":"Press Release: SL Science Holding Limited Reports Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2644390000","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644390000?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:13","pubTimestamp":1781817180,"startTime":"0","endTime":"0","summary":"Taipei, TAIWAN, June 18, 2026  --  SL Science Holding Limited  , a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced its financial results for the full year ended December 31, 2025.\"Looking ahead, with the vision of establishing one of the leading allogeneic Gamma Delta T cell platforms in Asia with global commercialization potential, our focus is squarely on regulatory preparedness and preclinical execution. For our CD-19 Armed-T blood cancer program, we are actively addressing the FDA's initial feedback by conducting additional nonclinical validation and manufacturing scale-ups, aiming for a Pre-Investigational New Drug  meeting and formal IND submission in the first quarter of 2027. Concurrently, our Unmodified GDT cell platform is progressing through technical transfers to an FDA-compliant contract development and manufacturing organization . Unlike traditional autologous therapies, our GDT cell approach is de","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDT","SLBT","IND","CDMO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644085147","title":"Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644085147","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644085147?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:00","pubTimestamp":1781784000,"startTime":"0","endTime":"0","summary":"Proceeds from transaction to support advancement of Denali’s broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/18/3314101/0/en/Denali-Therapeutics-Enters-Agreement-to-Sell-Rare-Pediatric-Disease-Priority-Review-Voucher-for-195-Million.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4100","BK4139","BK4539","BK4115","ETV","LABU","LENZ","BK4585","BK4588","TV","BBB","BK4007","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138086374","title":"Starbucks Intensifies Focus on India with Ambitious Store Expansion Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1138086374","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138086374?lang=en_us&edition=fundamental","pubTime":"2026-06-18 15:00","pubTimestamp":1781766040,"startTime":"0","endTime":"0","summary":"Despite facing pressures to adjust its global operations, Starbucks (SBUX.US) is accelerating its push into the Indian market. The coffee giant's joint venture with India's Tata Group, Tata Starbucks...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4610","INDE","EPI","BK4535","IND","INDL","BK4523","PIN","LU0823411888.USD","NDIA","SBUX","NFTY","SBU","LU0882574139.USD","SCIN","BK4504","FLIN","INDY","IE00B3T34201.USD","SMIN","BK4209","BK4585","INQQ","INDA","GLIN","BK4588","INCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644749918","title":"Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2644749918","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644749918?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:47","pubTimestamp":1781700420,"startTime":"0","endTime":"0","summary":"Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 202","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/17/3313445/0/en/Ernexa-Therapeutics-Positioned-to-Become-a-Clinical-Stage-Biotechnology-Company-as-ERNA-101-On-Track-for-Planned-Q3-2026-IND-Submission-and-First-in-Human-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643750538","title":"NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2643750538","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643750538?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:00","pubTimestamp":1781614800,"startTime":"0","endTime":"0","summary":"Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection of 6","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/16/3312654/0/en/NeOnc-Technologies-Secures-UAE-IND-Approval-for-NEO212-Following-Successful-Phase-1-Completion-Advancing-Toward-Global-Phase-2-Development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","UAE","IND","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643757846","title":"Calidi receives pre-IND regulatory feedback from FDA for CLD-401","url":"https://stock-news.laohu8.com/highlight/detail?id=2643757846","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643757846?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:39","pubTimestamp":1781613560,"startTime":"0","endTime":"0","summary":"Calidi (CLDI) announced that it has received pre-IND regulatory feedback from the FDA providing alignment and clarity on Calidi’s IND-enabling prec...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/calidi-receives-pre-ind-regulatory-feedback-from-fda-for-cld-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/calidi-receives-pre-ind-regulatory-feedback-from-fda-for-cld-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","LABU","IND","BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643875208","title":"Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643875208","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643875208?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:33","pubTimestamp":1781613180,"startTime":"0","endTime":"0","summary":"EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/16/3312598/0/en/Entera-Reports-Robust-Preclinical-Data-for-EB612-Oral-LA-PTH-1-34-for-Hypoparathyroidism-and-EB618-Oral-GLP-1-Glucagon-for-Obesity-at-ENDO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","ENDO","BK4196","OXM","BK4183","PTH","GLP","BK4144","ENTX","BK4590","BK4202","BK4139","OPK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643975276","title":"Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643975276","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643975276?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:00","pubTimestamp":1781611200,"startTime":"0","endTime":"0","summary":"IND enabling studies with CLD-401 to continue with IND submission targeted by end of 2026 as Calidi continues to explore regulatory filing for CLD-401 in Australia in parallelSAN DIEGO, June  16, 2026","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/16/3312482/0/en/Calidi-Biotherapeutics-Receives-Positive-Pre-IND-Feedback-from-US-FDA-for-CLD-401-Indicating-Agreement-on-its-Current-Development-Strategy-as-it-Advances-Towards-a-First-in-Human-S.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","IND","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643517217","title":"Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643517217","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643517217?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:32","pubTimestamp":1781609520,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, June  16, 2026  (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/16/3312463/0/en/Clearmind-Medicine-Completes-Dosing-for-Part-A-of-its-of-FDA-Regulated-Phase-I-II-Clinical-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643508209","title":"XBiotech to enroll patients in vilamakitug trial following FDA review","url":"https://stock-news.laohu8.com/highlight/detail?id=2643508209","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643508209?lang=en_us&edition=fundamental","pubTime":"2026-06-15 21:21","pubTimestamp":1781529699,"startTime":"0","endTime":"0","summary":"XBiotech (XBIT) announced that its investigational new drug, or IND, application for V-SPINE, a Phase II, double-blind, placebo-controlled, randomi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xbiotech-to-enroll-patients-in-vilamakitug-trial-following-fda-review-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xbiotech-to-enroll-patients-in-vilamakitug-trial-following-fda-review-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IND","BK4588","LABU","BK4139","XBIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643206760","title":"XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2643206760","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643206760?lang=en_us&edition=fundamental","pubTime":"2026-06-15 21:00","pubTimestamp":1781528400,"startTime":"0","endTime":"0","summary":"IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment AUSTIN, Texas, June  15, 2026  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/15/3311812/35550/en/XBiotech-Launches-Phase-II-Clinical-Trial-Evaluating-Vilamakitug-for-the-Treatment-of-Active-Axial-Spondyloarthritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4534","LU2125154778.USD","LU1244550221.USD","LU0203347892.USD","LU0320765646.SGD","LU0203345920.USD","LU1244550577.SGD","LU0130102774.USD","BK4207","LU0310800965.SGD","LU2417539215.USD","LU2125154935.USD","LU1791807156.HKD","LU0648001328.SGD","BK4585","BK4139","LU1162221912.USD","BK4504","LU0130517989.USD","LU2456880835.USD","IND","LU2462157665.USD","LU0098860793.USD","LU1668664300.SGD","LU2236285917.USD","IE00BSNM7G36.USD","LU2360032135.SGD","LU1366192091.USD","XBIT","LU0106831901.USD","BK4566","BK4559","LU0162691827.USD","LU1506573853.SGD","LU1267930227.SGD","LU0072461881.USD","LU1244550494.USD","LU0477156953.USD","LU0128525689.USD","LU0170899867.USD","LU0052756011.USD","LU1201861249.SGD","CUL3","LU0980610538.SGD","LU0314106906.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643219713","title":"HBM Holdings (SEHK:2142) Stock Valuation After New IND Milestone For Cancer Antibody HBM7004","url":"https://stock-news.laohu8.com/highlight/detail?id=2643219713","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643219713?lang=en_us&edition=fundamental","pubTime":"2026-06-13 11:28","pubTimestamp":1781321337,"startTime":"0","endTime":"0","summary":"HBM Holdings (SEHK:2142) is back in focus after China’s National Medical Products Administration accepted its investigational new drug filing for HBM7004, a bispecific antibody for advanced solid tumors, following earlier U.S. FDA clearance.\nSee our latest analysis for HBM Holdings.\nDespite the positive regulatory news, the stock’s recent momentum has cooled, with a 30 day share price return down 21.58% and the year to date share price return down 16.97%. This comes even as the 1 year total...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-stock-valuation-after-new-ind-mileston","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-stock-valuation-after-new-ind-mileston","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","BK4588","IND","BK1574","HBM","DRAM","BK4168","DCF","02142","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642625428","title":"Shanghai Bao Pharma Wins U.S. FDA IND Clearance for First Subcutaneous Ceftriaxone Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2642625428","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642625428?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:01","pubTimestamp":1781089264,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co Ltd Class H ( ($HK:2659) ) has shared an update. Shanghai Bao Pharmaceuticals has secured U.S. FDA approval of an i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/shanghai-bao-pharma-wins-u-s-fda-ind-clearance-for-first-subcutaneous-ceftriaxone-candidate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/shanghai-bao-pharma-wins-u-s-fda-ind-clearance-for-first-subcutaneous-ceftriaxone-candidate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","IND","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642848417","title":"HBM Wins China IND Nod for Bispecific Cancer Antibody HBM7004","url":"https://stock-news.laohu8.com/highlight/detail?id=2642848417","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642848417?lang=en_us&edition=fundamental","pubTime":"2026-06-10 12:37","pubTimestamp":1781066249,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. ( ($HK:2142) ) has issued an announcement. HBM Holdings Ltd. announced that China’s National Medical Products Administration has ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hbm-wins-china-ind-nod-for-bispecific-cancer-antibody-hbm7004?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hbm-wins-china-ind-nod-for-bispecific-cancer-antibody-hbm7004?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","BK4168","BK4588","HBM","DRAM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}